Ajinomoto licenses Corynex system to pharma company

Ajinomoto said based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of the system.

Corynex uses the gram-positive Corynebacterium glutamicum to reduce purification steps, lower costs, and increase yield.

The expression does not require cell lysis or protein refolding, which decimates the need for endotoxin removal steps.

The system also speeds up production through a fast-growing bacterial model, shorter fermentation run to produce proteins and cheaper bacterium medium cost.

Ajinomoto business manager Joel White said, "We are pleased to extend a licensing agreement with a top-tier pharmaceutical company to build upon our initial successful proof-of-concept efforts."